Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
复制标题
Donanemab 治疗后淀粉样蛋白减少与 Tau 病理学和临床结果的关系
作者：
S. Shcherbinin;C. D. Evans;M. Lu;S. Andersen;M. Pontecorvo;B. Willis;I. Gueorguieva;P. Hauck;D. Brooks;M. Mintun;J. Sims
这项随机临床试验的事后分析，即早期症状性阿尔茨海默病患者的 LY3002813 研究 (TRAILBLAZER-ALZ)，调查了多南单抗治疗中淀粉样蛋白的减少是否与早期症状性阿尔茨海默病患者的 tau 病理学减慢和临床衰退有关。
This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ), investigates if amyloid reduction from donanemab treatment is associated with slowing of tau pathology and clinical decline in individuals with early symptomatic Alzheimer disease.